Overview

Effects of Zoledronic Acid Versus Alendronate on Bone Loss After Kidney and Kidney/Pancreas Transplants

Status:
Completed
Trial end date:
2014-09-01
Target enrollment:
0
Participant gender:
All
Summary
The study is designed to look at the effect of different bone treatment plans on bone loss after kidney or kidney/pancreas transplant.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
University of Nebraska
Treatments:
Alendronate
Calcium
Calcium Carbonate
Calcium, Dietary
Diphosphonates
Ergocalciferols
Pancrelipase
Vitamin D
Vitamins
Zoledronic Acid
Criteria
Inclusion Criteria:

- Transplant patients who have had a kidney or kidney/pancreas transplant in the last
150 days with adequate kidney function as defined by a calculated creatine clearance
of 35ml/min or more and serum creatinine less than 3.0

Exclusion Criteria:

- Dual X-ray Absorptiometry (DXA) T-score at the spine or hip of -3 or lower

- History of more than one vertebral or non-vertebral fracture in the past two years

- Abnormalities of the esophagus which delay esophageal emptying

- Inability to stay upright for 30 minutes

- Pregnant, nursing women or women not using an effective form of birth control

- Hypocalcemia

- Hypercalcemia

- Calculated creatinine clearance of <35 ml/min or serum creatinine > 3.0

- Patients already treated with bisphosphonates within the past one year

- Patients unable to undergo DXA

- Patients with cancer